• Exploring PF/PD profiling of Contera’s lead ASO in non-human primates, including both juvenile and adult cohorts, with longitudinal measurements over 28 weeks to characterise tissue distribution, target engagement, and systemic exposure
• Validating target engagement and compound selectivity using non-invasive proton spectroscopy biomarkers
• Discover how extended preclinical evaluation in non-human primates informs translational development for establishing benchmarks for dosing, pharmacodynamic responses, and optimisation strategies for clinical readiness 

NEW DATA